Home  |   Companies  |   Targets  |   Drugs  |   Diseases  |   Search  |   Help  |   About Blog Blog | Twitter Twitter | Rss SciBite News | Contact Contact   
LogoBeta Software
Open Drug Discovery Intelligence
     
searchSearch Scibite.com

Targets, Diseases & Drug Names All News
a- A+
SCIBITE NEWS:

Economics of Helicobacter pylori eradication therapy
Wed Apr 25 16:14:23 BST 2012
Key Topics

Click on any of the topic names to view its own newsletter. The text we matched to the topic is shown in grey underneath.

 Peptic Ulcer

[matched:peptic ulcer, helicobacter pylori]

 Ulcer

[matched:peptic ulcer, helicobacter pylori]

 Gastritis

[matched:helicobacter pylori]

 Helicobacter Infections

[matched:helicobacter pylori]

   
: The annual incidence of peptic ulcer disease in developed countries is around one to three per thousand inhabitants. Since the introduction of acid-secretion inhibitors, the indirect costs of this disease, which has a high rate of relapse, have steadily decreased, although direct costs have been increasing. The possibility of healing the patient through Helicobacter pylori eradication has the potential for a huge economic impact considering the long-term cost: benefit ratio. A recent study has shown that H. pylori eradication therapy can save between US$750 000 and US$1 000 000 per year per million inhabitants in western Europe compared to maintenance or episodic therapy. This paper reviews the cost implications of various management strategies for peptic ulcer disease, comparing the cost: benefit ratios of five different treatment regimens;   Read more on this story here

Source: ncbi.nlm.nih.gov   (view original)
Inst: From the Brugmann University Hospital, Brussels, Belgium.
   abstracted provided by MEDLINE/PubMed, a database of the U.S. National Library of Medicine.

Summary Loaded